Joseph C. Papa Purchases 30,000 Shares of Bausch Health Companies Inc (NYSE:BHC) Stock
Bausch Health Companies Inc (NYSE:BHC) CEO Joseph C. Papa purchased 30,000 shares of the company’s stock in a transaction dated Friday, September 13th. The stock was bought at an average price of $23.31 per share, with a total value of $699,300.00.
Shares of Bausch Health Companies stock opened at $23.19 on Thursday. The firm has a market capitalization of $8.22 billion, a price-to-earnings ratio of 5.49, a PEG ratio of 0.28 and a beta of 0.80. Bausch Health Companies Inc has a fifty-two week low of $17.20 and a fifty-two week high of $28.45. The company has a debt-to-equity ratio of 8.94, a quick ratio of 0.92 and a current ratio of 1.21. The stock has a 50 day moving average of $22.27 and a 200 day moving average of $23.48.
Bausch Health Companies (NYSE:BHC) last issued its quarterly earnings data on Tuesday, August 6th. The company reported $1.03 earnings per share for the quarter, missing the consensus estimate of $1.06 by ($0.03). The business had revenue of $2.15 billion during the quarter, compared to analysts’ expectations of $2.15 billion. Bausch Health Companies had a positive return on equity of 52.12% and a negative net margin of 10.88%. The company’s revenue was up 1.1% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.93 earnings per share. Analysts forecast that Bausch Health Companies Inc will post 4.24 EPS for the current year.
BHC has been the subject of a number of analyst reports. Guggenheim initiated coverage on Bausch Health Companies in a research report on Thursday, September 12th. They issued a “buy” rating and a $30.00 price target for the company. Mizuho set a $45.00 price target on Bausch Health Companies and gave the company a “buy” rating in a research report on Thursday, June 20th. TD Securities upgraded Bausch Health Companies from a “hold” rating to a “buy” rating and set a $28.00 price target for the company in a research report on Thursday, August 15th. HC Wainwright upped their price target on Bausch Health Companies from $50.00 to $54.00 and gave the company a “buy” rating in a research report on Wednesday, August 7th. Finally, Barclays set a $28.00 price target on Bausch Health Companies and gave the company a “buy” rating in a research report on Monday, July 8th. Three equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and twelve have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $29.68.
About Bausch Health Companies
Bausch Health Companies Inc develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through four segments: Bausch + Lomb/International, Salix, Ortho Dermatologics, and Diversified Products.
Featured Article: Net Income
Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.